玉溪那家人流医院正规玉溪做人流那家医院好,玉溪做人流究竟要多少钱,玉溪打胎的医院哪家最好,玉溪那家做无痛人流好,玉溪去哪里打胎,玉溪市哪家的做人流做的好的,玉溪人流手术哪里好

White House looking at stricter travel banThe Trump administration is considering a new travel ban to replace its original executive order, which has had its legality questioned and is up for a Supreme Court hearing next month, White House national security adviser H.R. McMaster said Sunday.READ MORE  315

With Burger King bringing back its menu, the burger chain is celebrating by giving away money for fans to try it out.Currently, the company is depositing into random people's Venmo accounts to encourage people to check out the Your Way Menu.The menu will feature four items: bacon cheeseburger, chicken jr. sandwich, a value soft drink, and value fries. And they all cost . 392

While unofficial vote count totals show that Joe Biden has won the 2020 election and will become the 46th President of the United States, President Donald Trump has yet to concede. In fact, the Trump administration has so far blocked the transition process from getting underway.Trump has falsely claimed victory in the election on the unproven basis of widespread voter fraud. The campaign has filed several lawsuits in states where vote counts are tight, but it's unlikely that those lawsuits will result in a massive swing in votes needed to change the outcome of the election.However, there are a handful of Republican lawmakers that have recognized Joe Biden as the President-elect, and more still that have said the transition process should get underway while courts hear Trump's challenges.Below is a list of high-ranking Republicans currently in office that have congratulated Biden or called for the transition process to begin.Sen. Mike Rounds, South DakotaIn an interview with NBC News, Rounds, who won re-election earlier this month, did not directly respond to questions about Trump's claims of widespread voter fraud. However, he did say that "certain parts" of the transition team should "move forward."Sen. Marco Rubio, FloridaWhile Rubio has echoed the Trump administration's unsubstantiated claims of widespread voter fraud, falsely claiming that Republicans should be suspicious about mail-in voting. However, in an interview with Bloomberg News, Rubio said that the General Services Administration (GSA) should open up transition funds."We need to have that contingency in place," Rubio said. "I don't think allowing the GSA to move forward on some of the transition work prejudices in any way any of the legal claims the president intends to make."Sen. Ben Sasse, NebraskaAnother moderate Republican who won re-eleciton earlier this month, Sasse congratulated Biden in a statement issued to the Omaha World-Herald."Melissa and I congratulate the next president, Joe Biden, and the next vice president, Kamala Harris," the Nebraska Republican said in a statement. "Today in our house we pray for both President Trump and President-Elect Biden, that both would be wise in the execution of their respective duties during this important time in our nation."Sen. Pat Toomey, PennsylvaniaOn Nov. 10, the Republican senator told a Pittsburgh-area TV station that he thinks the Trump administration should begin the transition process."We're on a path it looks likely Joe Biden is going to be the next president of the United States. It's not 100% certain but it is quite likely. So I think a transition process ought to begin," Toomey told WTAE-TV.Gov. Mike DeWine, OhioIn an interview with CNN on Thursday, DeWine said that he recognizes Biden as President-elect, but added that the Trump administration has every right to challenge the results of the election."Look, I think that we need to consider the former vice president as the President-elect. Joe Biden is the President-elect," DeWine said. "The White House has every — the president and his campaign has every right to go into court. Our courts are open. Our courts are the best place, frankly, to adjudicate facts. We just all need to take a deep breath. There is a process for all of this. You need to follow the process. And we need to move this country forward."Sen. Mitt Romney, Utah 3371

With a coronavirus vaccine still months off, companies are rushing to test what may be the next best thing: drugs that deliver antibodies to fight the virus right away, without having to train the immune system to make them.Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. Vaccines work by tricking the body into thinking there’s an infection so it makes antibodies and remembers how to do that if the real bug turns up.But it can take a month or two after vaccination or infection for the most effective antibodies to form. The experimental drugs shortcut that process by giving concentrated versions of specific ones that worked best against the coronavirus in lab and animal tests.“A vaccine takes time to work, to force the development of antibodies. But when you give an antibody, you get immediate protection,” said University of North Carolina virologist Dr. Myron Cohen. “If we can generate them in large concentrations, in big vats in an antibody factory ... we can kind of bypass the immune system.”These drugs are believed to last for a month or more and could give quick, temporary immunity to people at high risk of infection, such as health workers and housemates of someone with COVID-19. If they proved effective and if a vaccine doesn’t materialize or protect as hoped, the drugs might eventually be considered for wider use, perhaps for teachers or other groups.They’re also being tested as treatments, to help the immune system and prevent severe symptoms or death.“The hope there is to target people who are in the first week of their illness and that we can treat them with the antibody and prevent them from getting sick,” said Dr. Marshall Lyon, an infectious disease specialist helping to test one such drug at Emory University in Atlanta.Having such a tool “would be a really momentous thing in our fight against COVID,” Cohen said.Vaccines are seen as a key to controlling the virus, which has been confirmed to have infected more than 20 million people worldwide and killed more than 738,000. Several companies are racing to develop vaccines, but the results of the large final tests needed to evaluate them are months away.The antibody drugs are “very promising” and, in contrast, could be available “fairly soon,” said Dr. Janet Woodcock, a U.S. Food and Drug Administration official who is leading government efforts to speed COVID-19 therapies. Key studies are underway and some answers should come by early fall.One company, Eli Lilly, has already started manufacturing its antibody drug, betting that studies now underway will give positive results.“Our goal is to get something out as soon as possible” and to have hundreds of thousands of doses ready by fall, said Lilly’s chief scientific officer, Dr. Daniel Skovronsky.Another company that developed an antibody drug cocktail against Ebola — Regeneron Pharmaceuticals Inc. — now is testing one for coronavirus.“The success with our Ebola program gives us some confidence that we can potentially do this again,” said Christos Kyratsous, a Regeneron microbiologist who helped lead that work.Regeneron’s drug uses two antibodies to enhance chances the drug will work even if the virus evolves to evade action by one.Lilly is testing two different, single-antibody drugs — one with the Canadian company AbCellera and another with a Chinese company, Junshi Biosciences. In July, Junshi said no safety concerns emerged in 40 healthy people who tried it and that larger studies were getting underway.Others working on antibody drugs include Amgen and Adaptive Biotechnologies. The Singapore biotech company Tychan Pte Ltd. also is testing an antibody drug and has similar products in development for Zika virus and yellow fever.“I’m cautiously optimistic” about the drugs, said the nation’s top infectious diseases expert, Dr. Anthony Fauci. “I’m heartened by the experience that we had with Ebola,” where the drugs proved effective.What could go wrong?— The antibodies may not reach all of the places in the body where they need to act, such as deep in the lungs. All the antibody drugs are given through an IV and must make their way through the bloodstream to wherever they’re needed.— The virus might mutate to avoid the antibody — the reason Regeneron is testing a two-antibody combo that binds to the virus in different places to help prevent its escape.Skovronsky said Lilly stuck with one antibody because manufacturing capacity would essentially be cut in half to make two, and “you will have less doses available.” If a single antibody works, “we can treat twice as many people,” he said.— The antibodies might not last long enough. If they fade within a month, it’s still OK for treatment since COVID-19 illness usually resolves in that time. But for prevention, it may not be practical to give infusions more often than every month or two.A San Francisco company, Vir Biotechnology Inc., says it has engineered antibodies to last longer than they usually do to avoid this problem. GlaxoSmithKline has invested 0 million in Vir to test them.Giving a higher dose also may help. If half of antibodies disappear after a month, “if you give twice as much, you will have two months’ protection,” Lilly’s Skovronsky said.— The big fear: Antibodies may do the opposite of what’s hoped and actually enhance the virus’s ability to get into cells or stimulate the immune system in a way that makes people sicker. It’s a theoretical concern that hasn’t been seen in testing so far, but large, definitive experiments are needed to prove safety.“As best as we can tell, the antibodies are helpful,” Lyon said.___Marilynn Marchione can be followed on Twitter: @MMarchioneAP___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5919

White House communications director Hope Hicks is not answering questions about her time in the White House during her closed-door House Intelligence Committee testimony Tuesday, but she has started to answer some questions about the presidential transition, according to lawmakers on the committee.A source familiar with her testimony says the attorney for Hicks told the committee that she will not discuss matters after the campaign in accordance with the White House request. When asked about certain matters, her attorney says she will "take it under advisement" but not answer those questions, the source said.When former White House chief strategist Steve Bannon appeared before the committee last month and didn't answer questions about similar time frame beyond the 2016 campaign, he was hit with a subpoena during the interview. Republicans said Bannon's claim that he could invoke executive privilege?during the presidential transition did not have merit.Hicks, however, did respond to some questions regarding the transition, according to Rep. Tom Rooney, a Florida Republican.Rooney said her answers weren't prompted by a subpoena threat, but because she apparently had responded to similar questions during her previous interview before the Senate Intelligence Committee. The committee made the case they were entitled to the same answers as the Senate panel, and the White House apparently agreed."It had more to do with what she testified to the Senate, and what was fair to the House to ask the same questions," Rooney said.It's unclear whether Hicks is answering all questions about the transition or just those that she previously answered in her Senate testimony.Earlier on Tuesday, Democrats were pushing for the committee to subpoena Hicks for not responding to the panel's questions."We got Bannon-ed," said Rep. Denny Heck, a Washington state Democrat."I have less hope we'll get to all the answers," said Rep. Mike Quigley, an Illinois Democrat. "As with anyone who doesn't answer questions, they ought to be subpoenaed."Rooney and other lawmakers said Hicks still was not answering questions about her time in the Trump White House."There are some questions that she's not going to answer. I think anything dealing with the administration, from the time of the inauguration," GOP Rep. Chris Stewart of Utah told reporters.Rep. Mike Conaway, the Texas Republican leading the House Intelligence Committee's Russia investigation, told CNN ahead of the meeting that he expected Hicks to answer all of the committee's questions. He declined to comment Tuesday afternoon on Hicks' testimony or a possible subpoena, saying he would wait until the interview had concluded.Bannon returned under subpoena earlier this month to the committee to continue he testimony, and he told the panel he had been instructed by the White House to invoke executive privilege on behalf of the President.California Rep. Adam Schiff, the top Democrat on the House Intelligence Committee, has called for Bannon to be held in contempt of Congress for refusing to answer questions, as well as former Trump campaign manager Corey Lewandowski, who also limited the scope of questions he would answer. But Conaway said Tuesday that he still has to discuss the matter with House Speaker Paul Ryan before deciding how to proceed.Quigley said Hicks had not asserted privilege Tuesday, but she was "following the orders of the White House not to answer certain questions."Hicks did not answer reporter questions on her way into the interview Tuesday morning. She was initially scheduled to appear before the committee last month as part of the panel's investigation into Russian meddling into the US election, but her interview was delayed over questions about the scope of her testimony.Hicks has already been interviewed by the Senate Intelligence Committee, a source familiar with the matter told CNN. Hicks also met last year with?special counsel Robert Mueller as part of his investigation.Hicks, a trusted Trump aide for years, was one of then-candidate Trump's first hires as he put together an improbable run for the White House. During the campaign, she was often by Trump's side and attended nearly every rally, while she was in frequent communication with other senior officials as they coordinated their tactics to win the White House.The House panel plans to interview her about any knowledge she has of contacts that occurred between other Trump associates and Russians. And she is bound to be questioned about other controversies as well, namely the White House's involvement in crafting a misleading response last summer once a June 2016 meeting between Russians and Donald Trump Jr. was revealed in the press.Hicks appears to have firsthand knowledge of a number of key events that have shaped the first year of the Trump White House, including being on Air Force One when the initial misleading statement about Trump Jr.'s meeting with Russians was crafted. 4977